Open Innovation in Pharmaceutical R&D
Life Science Event - Amsterdam, The Netherlands
In previous decades, traditional R&D methods have yielded blockbuster drugs, allowing companies to recoup the costs of development. Nowadays, with patent expiries, more complex disease targets, pricing pressures and increased regulatory requirements, the industry must find a different model to adapt to these changes.
As we are experiencing a lag between R&D spending and the extraction of value from that investment, open innovation presents an opportunity to break the mold of current drug research, innovate exponentially without expanding R&D investment and speed the development of tomorrow's lifesaving medicines for diseases.
Key Topics:
The challenges of sustained productivity:
Are we on the “patent cliff“ as the patents for blockbuster drugs expire?
Could Open Innovation provide answers to these challenges?
Is sharing of intellectual property a barrier to Open Innovation?
Engaging in Public-Private Partnerships to enhance drug development
Successful examples of sharing patents, compounds, data and expertise:
Collaboration between Academia and the corporate sector, Crowd sourcing initiatives, Neglected diseases drug discovery, etc.
Website: http://pharma.flemingeurope.com/innovation-pharma-rd
Thursday, April 26 to Friday, April 27, 2012
Crowne Plaza Amsterdam-South, Amsterdam, The Netherlands
Contact: (peter.novak@flemingeurope.com)
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
